FOLH1 and posterior cortical atrophy: The PROPELLER trial (NCT04839367), a Phase I study in newly diagnosed PCa patients, confirmed safety and showed higher lesion uptake of [64Cu]Cu-SAR-bisPSMA compared to [68Ga]Ga-PSMA-11 [130].